рекомендации при множественной миеломе. Удк национальные клинические рекомендации по диагностике и лечению множественной миеломы
 Скачать 0.65 Mb.
|
|
Cancer. 2009; 115(1): 229–32. doi: 10.1002/cncr.24006. • Weber D.M., Chen C., Niesvizky R., Wang M., Belch A., Stadtmauer E.A., et al.; Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med. 2007; 357(21): 2133–42. • Bessmeltsev S.S., Karyagina E.V., Stelmashenko L.V., Stepanova N.V., Machyulaytene E.R., Salogub G.N., et al. Frequency, characteristics and methods of treatment of peripheral neuropathy in patients with multiple myeloma, receiving bortezomib (Velcade). Onkogematology. Russian journal (Onkogematologiya). 2008; 3: 52–62. (in Russian) • Votyakova O.M. Multiple myeloma. In: Perevodchikova N.I., ed. Guide to chemotherapy tumor diseases. Moscow: Practical Meditsine; 2011: 362–72. (in Russian) • Votyakova O.M., Osmanov D.Sh., Demina E.A., Falaleeva N.A., Byalik T.E., Ryabukhina Yu.E., et al. Use of Velcade in multiple myeloma. Therapeutic archive. Russian journal (Terapevticheskiy arkhiv). 2007; 7: 70–3. (in Russian) • Davydov M.I., Axel E.M. Statistics malignant neoplasms of Russia and Union of Independent States 2007. Bulletin of N.N. Blokhin’s Russian Cancer Research Center. 2009; 3(Suppl. 1): 1–156. (in Russian) • Chissov V.I., Starinskiy V.V., Petrova G.V., eds. Malignant neoplasms in Russia in 2011 (morbidity and mortality). Moscow: P.A. Gertsen’s Moscow Cancer Institute; 2013. (in Russian) • Mendeleeva L.P. Modern treatment of multiple myeloma. Clinical oncohaematology. Basic research and clinical practice. Russian journal (Klinicheskaya onkogematologiya. Fundamentalnye issledovaniya i klinicheskaya praktika). 2009; 1: 64–5. (in Russian) • Pokrovskaya O.S., Mendeleeva L.P., Urnova E.S., Gaponova T.V., Galtseva I.V., Kuzmina L.A., et al. Effect of bortezomib on the efficiency of mobilization of hematopoietic stem blood cells in patients with multiple myeloma. Therapeutic archive. Russian journal (Terapevticheskiy arkhiv). 2012; 7: 35–41. (in Russian) failure and improved quality of life compared to treatment with melphalan and prednisone – a randomized phase III study of East German Study Group of Hematology and Oncology (OSH). J. Cancer Res. Clin. Oncol. 2006; 132(4): 205–12. • Rajkumar S.V., Harousseau J.L., Durie B., Anderson K.C., Dimopoulos M., Kyle R., et al.; International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011; 117(18): 4691–5. doi: 10.1182/blood-2010-10-299487. • Rajkumar S.V., Jacobus S., Callander N.S., Fonseca R., Vesole D.H., Williams M.E., et al.; Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010; 11(1): 29–37. doi: 10.1016/ S1470-2045(09)70284-0. • Rajkumar S.V., Kyle R.A., eds. Treatment of Multiple Myeloma and Relation Disorders. Cambridge University Press; 2009. • Reece D.E., Masih-Khan E., Khan A., et al. Phase I–II trial of oral cyclophosphamide, prednisone and lenalidomide (Revlimid®) (CPR) for the treatment of patients with relapsed and refractory multiple myeloma [abstract]. Blood (ASH Annual Meeting Abstracts). 2010; 116(21): 3055. • Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 2003; 348(26): 2609–17. • Richardson P.G., Delforge M., Beksac M., Wen P., Jongen J.L., Sezer O., et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia. 2012; 26(4): 595– 608. doi: 10.1038/leu.2011.346. • Richardson P.G., Jagannath S., Jakubowiak A.J., et al. Phase II trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma: updated efficacy and safety data after >2 years of follow-up. Blood (ASH Annual Meeting Abstracts). 2010; 1169210: 3049. • Richardson P.G., Sonneveld P., Schuster M., Irwin D., Stadtmauer E., Facon T., et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007; 110(11): 3557–60. • Richardson P.G., Weller E., Lonial S., Jakubowiak A.J., Jagannath S., Raje N.S., et al. Lenalidomide, bortezomib and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010; 116(5): 679–86. doi: 10.1182/blood-2010-02-268862. • Rodon Ph., Hulin C., Pegourie Br., et al. Bendamustine, bortezomib and dexamethasone (BVD) in elderly patients with multiple myeloma in first relapse: final analysis of the intergroupe francophone du myelome (IFM) 2009-01 trial. (ASH 2013 Annual Meeting Abstract) Blood. 2013; 122(21): 1971. • Rosinol L., Cibeira M.T., Uniburu C., Yantorno S., Salamero O., Bladé J., Montserrat E. Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur. J. Haematol. 2006; 76(5): 405–8. • San Miguel J.F., Schlag R., Khuageva N.K., Dimopoulos M.A., Shpilberg O., Kropff M., et al.; VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 2008; 359(9): 906–17. doi: 10.1056/NEJMoa0801479. • San-Miguel J.F., Dimopoulos M.A., Stadtmauer E.A., Rajkumar S.V., Siegel D., Bravo M.L., et al. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin. Lymphoma Myeloma Leuk. 2011; 11(1): 38–43. doi: 10.3816/CLML.2010.n.120. • San-Miguel J., Harousseau J.L., Joshua D., Anderson K.C. Individualizing treatment of patients with myeloma in the era of novel agents. J. CLin. Oncol. 2008; 26(16): 2761–6. doi: 10.1200/JCO.2007.15.2546. • San Miguel J., Weisel K., Moreau P., Lacy M., Song K., Delforge |